System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Review Epublish 2 citations

PubMed: 40144393 DOI: 10.3389/fbioe.2025.1547025

mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy.

Front Bioeng Biotechnol 13:1547025

Authors: Dariush Haghmorad, Majid Eslami, Niloufar Orooji, Iryna Halabitska, Iryna Kamyshna, Oleksandr Kamyshnyi, Valentyn Oksenych

Affiliations

  • Department of Immunology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran.
  • Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran.
  • Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
  • Department of Therapy and Family Medicine, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
  • Department of Medical Rehabilitation, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
  • Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.

Abstract

The advent of mRNA vaccines, accelerated by the global response to the COVID-19 pandemic, marks a transformative shift in vaccine technology. In this article, we discuss the development, current applications, and prospects of mRNA vaccines for both the prevention and treatment of infectious diseases and oncology. By leveraging the capacity to encode antigens within host cells directly, mRNA vaccines provide a versatile and scalable platform suitable for addressing a broad spectrum of pathogens and tumor-specific antigens. We highlight recent advancements in mRNA vaccine design, innovative delivery mechanisms, and ongoing clinical trials, with particular emphasis on their efficacy in combating infectious diseases, such as COVID-19, Zika, and influenza, as well as their emerging potential in cancer immunotherapy. We also address critical challenges, including vaccine stability, optimization of immune responses, and the broader issue of global accessibility. Finally, we review potential strategies for advancing next-generation mRNA vaccines, with the aim of overcoming current limitations in vaccine technology and enhancing both preventive and therapeutic approaches for infectious and oncological diseases.

MeSH

Vaccines, Neoplasms, Rna, Messenger, Immunotherapy, Therapeutics, Communicable Diseases, Vaccine Development

Cited by